PD-1 and its receptor (PD-L1) are crucial immune checkpoints in tumors, and the binding of PD-L1 and PD-1 restrains the anti-tumor function of T-cell(s) and enhances regulatory T-cell activation, which enables tumors to achieve immune evasion [20,21]. The gene discussed is CD274; the disease is neoplasm.